Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Achieving longer remissions with venetoclax monotherapy in R/R CLL

Venetoclax monotherapy has been shown to extend progression-free survival (PFS) in relapsed/refractory chronic lymphocytic leukemia (CLL) patients. In a post-hoc analysis of different trials, William Wierda, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, and colleagues, have looked at the link between PFS and depth of response in two patient cohorts receiving venetoclax monotherapy in the relapsed/refractory setting. In this interview, Prof Wierda explores the results presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.